financetom
Business
financetom
/
Business
/
Australia's Westpac to sell auto finance loan book to Resimac Group
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Australia's Westpac to sell auto finance loan book to Resimac Group
Oct 2, 2024 9:46 PM

(Reuters) - Westpac Banking Corp ( WEBNF ) said on Thursday it would sell its auto finance loans book to non-bank lender Resimac Group for an expected value of A$1.4 billion ($963.62 million) to A$1.6 billion at completion.

Westpac, Australia's second-largest mortgage lender by loans, had partially sold its auto finance business to U.S. private equity firm Cerberus Capital Management in 2021, as it moved to focus on core banking operations.

"The transaction supports the strategic growth objectives of Resimac's asset finance division and follows a number of business and portfolio acquisitions in recent years," Resimac said in a separate statement.

The deal is expected to complete by the first half of 2025.

($1 = 1.4529 Australian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-AUO Announces Sale Of Plant In Taiwan To Micron Technology
BRIEF-AUO Announces Sale Of Plant In Taiwan To Micron Technology
Aug 27, 2024
Aug 27 (Reuters) - Auo: * ANNOUNCES SALE OF PLANT IN SOUTHERN TAIWAN TO MICRON TECHNOLOGY FOR T$7.4 BILLION ($232.7 MLN) * SAYS THE ASSET DISPOSAL WOULD YIELD ESTIMATED DIVESTMENT RETURN OF T$4.174 BILLION * SAYS ONE OF ITS UNITS HAS SOLD ANOTHER FACILITY TO MICRON TECHNOLOGY FOR T$700 MILLION, YIELDING DIVESTMENT RETURN OF T$544 MILLION Source text for Eikon:...
Merck Initiates Phase 3 Trial to Evaluate Essential Thrombocythemia Treatment Candidate
Merck Initiates Phase 3 Trial to Evaluate Essential Thrombocythemia Treatment Candidate
Aug 27, 2024
07:18 AM EDT, 08/27/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday it has initiated a phase 3 clinical trial to evaluate bomedemstat, an investigational LSD1 inhibitor, for treating essential thrombocythemia in patients who have not previously received cytoreductive therapy. The trial, which is enrolling around 300 patients, will compare bomedemstat to the standard chemotherapy treatment, hydroxyurea. The primary...
Market Chatter: Adobe, Microsoft, OpenAI Back California Bill Requiring Watermarks on AI Content
Market Chatter: Adobe, Microsoft, OpenAI Back California Bill Requiring Watermarks on AI Content
Aug 27, 2024
07:22 AM EDT, 08/27/2024 (MT Newswires) -- Adobe (ADBE) Microsoft ( MSFT ) , and Microsoft ( MSFT )-backed OpenAi are backing a proposed California law that would require watermarks in the metadata of images, video, and audio generated by artificial intelligence tools, TechCrunch reported Monday, according to letters it examined. The California Digital Content Provenance Standards bill under consideration...
Eli Lilly Releases Single-Dose Vials of Obesity Drug Zepbound
Eli Lilly Releases Single-Dose Vials of Obesity Drug Zepbound
Aug 27, 2024
07:19 AM EDT, 08/27/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that single-dose vials of its Zepbound treatment for obesity in adults are now available for self-paying patients with on-label prescriptions, expanding access to the product. The vials come in 2.5-milligram and 5mg doses and are available through a new self-pay pharmacy division of the company's LillyDirect,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved